These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 24816255)

  • 1. Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma.
    Kakiuchi M; Nishizawa T; Ueda H; Gotoh K; Tanaka A; Hayashi A; Yamamoto S; Tatsuno K; Katoh H; Watanabe Y; Ichimura T; Ushiku T; Funahashi S; Tateishi K; Wada I; Shimizu N; Nomura S; Koike K; Seto Y; Fukayama M; Aburatani H; Ishikawa S
    Nat Genet; 2014 Jun; 46(6):583-7. PubMed ID: 24816255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sporadic Early-Onset Diffuse Gastric Cancers Have High Frequency of Somatic CDH1 Alterations, but Low Frequency of Somatic RHOA Mutations Compared With Late-Onset Cancers.
    Cho SY; Park JW; Liu Y; Park YS; Kim JH; Yang H; Um H; Ko WR; Lee BI; Kwon SY; Ryu SW; Kwon CH; Park DY; Lee JH; Lee SI; Song KS; Hur H; Han SU; Chang H; Kim SJ; Kim BS; Yook JH; Yoo MW; Kim BS; Lee IS; Kook MC; Thiessen N; He A; Stewart C; Dunford A; Kim J; Shih J; Saksena G; Cherniack AD; Schumacher S; Weiner AT; Rosenberg M; Getz G; Yang EG; Ryu MH; Bass AJ; Kim HK
    Gastroenterology; 2017 Aug; 153(2):536-549.e26. PubMed ID: 28522256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic and Pathologic Profiling of Very Well-Differentiated Gastric Adenocarcinoma of Intestinal Type: A Study With Emphasis on Diffuse-Type Transformation.
    Rokutan H; Arai Y; Kunita A; Yamasaki S; Nakamura H; Hama N; Nakayama A; Hosoda F; Totoki Y; Fujishiro M; Seto Y; Shibata T; Ushiku T
    Am J Surg Pathol; 2024 Jun; 48(6):652-661. PubMed ID: 38584451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gain-of-Function
    Zhang H; Schaefer A; Wang Y; Hodge RG; Blake DR; Diehl JN; Papageorge AG; Stachler MD; Liao J; Zhou J; Wu Z; Akarca FG; de Klerk LK; Derks S; Pierobon M; Hoadley KA; Wang TC; Church G; Wong KK; Petricoin EF; Cox AD; Lowy DR; Der CJ; Bass AJ
    Cancer Discov; 2020 Feb; 10(2):288-305. PubMed ID: 31771969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant alternative splicing of RHOA is associated with loss of its expression and activity in diffuse-type gastric carcinoma cells.
    Miyamoto S; Nagamura Y; Nakabo A; Okabe A; Yanagihara K; Fukami K; Sakai R; Yamaguchi H
    Biochem Biophys Res Commun; 2018 Jan; 495(2):1942-1947. PubMed ID: 29247652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological characteristics of RHOA mutations in a Central European gastric cancer cohort.
    Röcken C; Behrens HM; Böger C; Krüger S
    J Clin Pathol; 2016 Jan; 69(1):70-5. PubMed ID: 26251521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RhoA mutations identified in diffuse gastric cancer.
    Zhou J; Hayakawa Y; Wang TC; Bass AJ
    Cancer Cell; 2014 Jul; 26(1):9-11. PubMed ID: 25026207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RHOA mutation in diffuse-type gastric cancer: a comparative clinicopathology analysis of 87 cases.
    Ushiku T; Ishikawa S; Kakiuchi M; Tanaka A; Katoh H; Aburatani H; Lauwers GY; Fukayama M
    Gastric Cancer; 2016 Apr; 19(2):403-411. PubMed ID: 25823974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastric poorly cohesive carcinoma: a correlative study of mutational signatures and prognostic significance based on histopathological subtypes.
    Kwon CH; Kim YK; Lee S; Kim A; Park HJ; Choi Y; Won YJ; Park DY; Lauwers GY
    Histopathology; 2018 Mar; 72(4):556-568. PubMed ID: 28873240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-31 inhibits RhoA-mediated tumor invasion and chemotherapy resistance in MKN-45 gastric adenocarcinoma cells.
    Korourian A; Roudi R; Shariftabrizi A; Madjd Z
    Exp Biol Med (Maywood); 2017 Dec; 242(18):1842-1847. PubMed ID: 28836853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variegated RHOA mutations in adult T-cell leukemia/lymphoma.
    Nagata Y; Kontani K; Enami T; Kataoka K; Ishii R; Totoki Y; Kataoka TR; Hirata M; Aoki K; Nakano K; Kitanaka A; Sakata-Yanagimoto M; Egami S; Shiraishi Y; Chiba K; Tanaka H; Shiozawa Y; Yoshizato T; Suzuki H; Kon A; Yoshida K; Sato Y; Sato-Otsubo A; Sanada M; Munakata W; Nakamura H; Hama N; Miyano S; Nureki O; Shibata T; Haga H; Shimoda K; Katada T; Chiba S; Watanabe T; Ogawa S
    Blood; 2016 Feb; 127(5):596-604. PubMed ID: 26574607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo effects of mutant RHOA on tumor formation in an orthotopic inoculation model.
    Nishizawa T; Nakano K; Fujii E; Komura D; Kuroiwa Y; Ishimaru C; Monnai M; Aburatani H; Ishikawa S; Suzuki M
    Oncol Rep; 2019 Nov; 42(5):1745-1754. PubMed ID: 31485674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of "regulation of RhoA activity panel" as a prognostic and predictive biomarker for gastric cancer.
    Huang W; Zhao S; Zhang C; Li Z; Ge S; Lian B; Feng H; Wang K; Xu R; Ji J; Gao J; Shi W; Shen L
    Aging (Albany NY); 2020 Dec; 13(1):714-734. PubMed ID: 33288739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RHOA mutations and CLDN18-ARHGAP fusions in intestinal-type adenocarcinoma with anastomosing glands of the stomach.
    Hashimoto T; Ogawa R; Tang TY; Yoshida H; Taniguchi H; Katai H; Oda I; Sekine S
    Mod Pathol; 2019 Apr; 32(4):568-575. PubMed ID: 30425335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RHOA
    Schaefer A; Hodge RG; Zhang H; Hobbs GA; Dilly J; Huynh MV; Goodwin CM; Zhang F; Diehl JN; Pierobon M; Baldelli E; Javaid S; Guthrie K; Rashid NU; Petricoin EF; Cox AD; Hahn WC; Aguirre AJ; Bass AJ; Der CJ
    Sci Signal; 2023 Dec; 16(816):eadg5289. PubMed ID: 38113333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer.
    Wang K; Yuen ST; Xu J; Lee SP; Yan HH; Shi ST; Siu HC; Deng S; Chu KM; Law S; Chan KH; Chan AS; Tsui WY; Ho SL; Chan AK; Man JL; Foglizzo V; Ng MK; Chan AS; Ching YP; Cheng GH; Xie T; Fernandez J; Li VS; Clevers H; Rejto PA; Mao M; Leung SY
    Nat Genet; 2014 Jun; 46(6):573-82. PubMed ID: 24816253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RAS and RHO family GTPase mutations in cancer: twin sons of different mothers?
    Hodge RG; Schaefer A; Howard SV; Der CJ
    Crit Rev Biochem Mol Biol; 2020 Aug; 55(4):386-407. PubMed ID: 32838579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histological and mutational profile of diffuse gastric cancer: current knowledge and future challenges.
    Garcia-Pelaez J; Barbosa-Matos R; Gullo I; Carneiro F; Oliveira C
    Mol Oncol; 2021 Nov; 15(11):2841-2867. PubMed ID: 33724653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversal of the malignant phenotype of gastric cancer cells by inhibition of RhoA expression and activity.
    Liu N; Bi F; Pan Y; Sun L; Xue Y; Shi Y; Yao X; Zheng Y; Fan D
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6239-47. PubMed ID: 15448013
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accuracy of Hereditary Diffuse Gastric Cancer Testing Criteria and Outcomes in Patients With a Germline Mutation in CDH1.
    van der Post RS; Vogelaar IP; Manders P; van der Kolk LE; Cats A; van Hest LP; Sijmons R; Aalfs CM; Ausems MG; Gómez García EB; Wagner A; Hes FJ; Arts N; Mensenkamp AR; van Krieken JH; Hoogerbrugge N; Ligtenberg MJ
    Gastroenterology; 2015 Oct; 149(4):897-906.e19. PubMed ID: 26072394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.